NCT03440437: FS118 First in Human Study in Patients With Advanced Malignancies After PD-1/PD-L1 Containing Therapy

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Uncontrolled CNS metastases, primary CNS tumors, or solid tumors with CNS metastases as only measurable disease

Comments are closed.

Up ↑